Pharmacokinetic interaction of some antitubercular drugs with caraway: Implications in the enhancement of drug bioavailability

Human and Experimental Toxicology

Volumn 28, Issue 4, 2009, Pages 175-184

  Sachin, B S ^a   Monica, P ^a   Sharma, S C ^a   Satti, N K ^a   Tikoo, M K ^a   Tikoo, A K ^a   Suri, K A ^a   Gupta, B D ^a   Johri, R K ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Caraway; Carum carvi bioavailability enhancement; Isoniazid; Permeation; Pyrazinamide; Rifampicin

Indexed keywords

BUTANOL; ISONIAZID; PENETRATION ENHANCING AGENT; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CARAWAY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE ABSORPTION; SURFACE PROPERTY; WISTAR RAT;

ANIMALS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARUM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FEMALE; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; ISONIAZID; JEJUNUM; MALE; PLANT EXTRACTS; PYRAZINAMIDE; RATS; RATS, WISTAR; REFERENCE STANDARDS; RIFAMPIN; SEEDS; SOLVENTS;

CARUM CARVI; RATTUS NORVEGICUS;

EID: 70049115978     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327108097431     Document Type: Article

References (33)

1. Khatri GR.,. Controlling tuberculosis in India. New Eng J Med 2002 ; 347: 1420 " 1425.
2. Yee D., Valiquette C., Pelletier M., Parisien I., Rocher I., Menzies D.,. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003 ; 167: 1472 " 1477.
3. Gulbay BE., Gurkan OU., Yildiz OA., Onen ZP., Erkekol FO., Baççlulu A. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 2006 ; 100: 1834 " 1842.
4. Tam CM., Yew WW., Leung CC., Chan YC.,. CDC recommendations against the use of rifampicin and pyrazinamide for treatment of latent tuberculosis infection. MMWR 2003 ; 6: 735 " 739.
5. Tasduq S.A., Kaiser P., Sharma SC., Johri RK.,. Potentiation of isoniazid-induced liver toxicity by rifampicin in a combination therapy of anti-tubercular drugs (rifampicin, isoniazid and pyrazinamide) in wistar rats: a toxicity profile study. Hepatol Res 2007 ; 37: 845 " 853.
6. Tasduq SA., Kaiser P., Koul S., Bhat R., Johri RK.,. Biochemical manifestations of anti-tubercular drugs induced hepatotoxicity and the effect of silymarin. Hepatol Res 2006 ; 31: 132 " 135.
7. Chan K., Liu ZQ., Jiang ZH., Zhou H., Wong YF., Xu HX.,. The effects of sinomenine on intestinal absorption of paeoniflorin by the everted rat gut sac model. J Ethnopharmacol 2006 ; 103: 425 " 432.
8. Lowry OH., Rosebrough NJ., Farr AL., Randall RJ.,. Protein measurement with Folin phenol reagent. J Biol Chem 1951 ; 193: 265 " 275.
9. KS Mhaskar., E Blatter., JF Caius., (). Kiritikar & Basu™s illustrated indian medicinal plants, vol. 5. New Delhi: Satguru Publications ; 2000. p. 1670 " 1672.
10. Tahraoui A., El-Hilaly J., Israili ZH., Lyoussi B.,. Ethnopharmacological survey of plants used in the traditional treatment of hypertension and diabetes in south-Eastern Morrocco (Errachidia province). J Ethnopharmacol 2007 ; 110: 1105 " 1117.
11. Khan S., Balick MJ.,. Therapeutic plants of Ayurveda: a review of selected clinical and other studies for 166 species. J Alt Complem Med 2001 ; 7: 405 " 415.
12. Iacobellis NS., Lo Cantore P., Capasso F., Senatore F.,. Antibacterial activity of Cuminum cyminum L. and Carum carvi L. essential oils. J Agri Food Chem 2005 ; 53: 57 " 61.
13. Naderi-Kalali B., Allameh A., Rasaee MJ., Bach HJ., Behechti A., Doods K.,. [REMOVED HYPERLINK FIELD] et al. Suppressive effects of caraway (Carum carvi) extracts on 2,3,4,7,8-tetrachlorodibenzo-p- dioxindependent gene expression of cytochrome P450 1A1 in the rat H4IIE cells. Toxicol in Vitro 2005 ; 19: 373 " 377.
14. Mazaki M., Kataoka K., Kinouchi T., Vinitketkumnuen U., Yamada M., Nohmi T.,. Inhibitory effects of caraway (Carum carvi L.) and its component on N-methyl-N™-nitro-N-nitrosoguanidine-induced mutagenicity. J Med Invest 2006 ; 53: 123 " 133.
15. Kamaleeswari M., Deeptha K., Sengottuvelan M., Nalini N.,. Effect of dietary caraway (Carum carvi L.) on aberrant crypt foci development, fecal steroids, and intestinal alkaline phosphatase activities in 1,2- dimethylhydrazine-induced colon carcinogenesis. Toxicol Appl Pharmacol 2006 ; 214: 290 " 296.
16. Kamaleeswari M., Nalini N.,. Dose-response efficacy of caraway (Carum carvi L.) on tissue lipid peroxidation and antioxidant profile in rat colon carcinogenesis. J Pharm Pharmacol 2006 ; 58: 1121 " 1130.
17. Deeptha K., Kamaleeswari M., Sengottuvelan M., Nalini N.,. Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine-induced colonic aberrant crypt foci and bacterial enzyme activity in rats. Invest New Drugs 2006 ; 24: 479 " 488.
18. Lemhadri A., Hajji L., Michel JB., Eddouks M.,. Cholestrol and triglycerides lowering activities of caraway fruits in normal and streptozotocin diabetic rats. J Ethnopharmacol 2006 ; 106: 321 " 326.
19. Lahlou S., Tahraoui A., Israili Z., Lyoussi B.,. Diuretic activity of the aqueous extracts of Carum carvi and Tanacetum vulgare in normal rats. J Ethnopharmacol 2007 ; 110: 458 " 463.
20. Eddouks M., Lemhadri A., Michel JB.,. Caraway and caper: potential anti-hyperglycaemic plants in diabetic rats. J Ethnopharmacol 2004 ; 94: 143 " 148.
21. Satyanarayana S., Sushruta K., Sarma G.S., Srinivas N., Subba Raju GV.,. Antioxidant activity of the aqueous extracts of spicy food additives- evaluation and comparison with ascorbic acid in in-vitro systems. J Herbal Pharmacother 2004 ; 4: 1 " 10.
22. Khayyal MT., el-Ghazaly MA., Kenaway SA., Seif-el-Nasr M., Mahran LG., Kafafi YA.,. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittelforschung 2001 ; 51: 545 " 553.
23. Mhady GB., Pendland SL., Stoia A., Hamill FA., Fabricant D., Dietz BM.,. In vitro susceptibility of Heliobactor pylori to botanical extracts used traditionally for the treatment of gastrointestinal disorders. Phytother Res 2005 ; 19: 988 " 991.
24. Zhou S., Lim LY., Chowbay B.,. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004 ; 36: 1 " 48.
25. Venkataramanan R., Komoroski B., Strom S.,. In vitro and in vivo assessment of herb drug interactions. Life Sci 2006 ; 78: 2105 " 2115.
26. Pal D., Mitra AK.,. MDR- and CYP3A4-mediated drug "herbal interactions. Life Sci 2006 ; 78: 2131 " 2145.
27. Petri WA.,. Drugs used in the chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: JG Hardman., LE Limberd., (eds). Goodman and Gilman™s the pharmacological basis of theapeutics, 10th ed. New York: McGraw Hill Medical Publishing Division ; 2001. p. 1273 " 1294.
28. Williams RL.,. Bioequivalence and therapeutic equivalence. In: PG Welling., FLS Tse., SV Dighe., (eds). Pharmaceutical bioequivalence. New York: Marcel Dekker Inc ; 1991. p. 1 " 15.
29. Brown JR., Collett JH., Attwood D., Ley RW., Sims EE.,. Influence of monocaprin on the permeablity of a diacidic drug BTA-243 across Caco-2 cell monolayers and everted gut sacs. Int J Pharmaceutics 2002 ; 245: 133 " 142.
30. Bennet LZ., Cummins CL.,. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001 ; 50: S3 " S11.
31. Williamson EM.,. Synergy and other interactions in phytomedicines. Phytomedicine 2001 ; 8: 401 " 412.
32. Spinella M.,. The importance of pharmacological synergy in psychoactive herbal medicines. Alt Med Rev 2002 ; 7: 130 " 142.
33. Aungst BJ.,. Intestinal permeation enhancers. J Pharm Sci 2000 ; 89: 429 " 442.